Sign in
4

Changes in Ownership

Xenon Pharmaceuticals Inc. Filed Acc 0001209191-22-049015

Chief Financial Officer sold 15,355 shares at $39.57 ($607,597)

  • Chief Financial Officer gave up 3,293 shares (to pay taxes)
  • Chief Financial Officer acquired 18,648 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I In the form
AULIN SHERRY Chief Financial Officer 2022-09-02 Option exercise +9,000 $9.44 $84,960 9,000 D
AULIN SHERRY Chief Financial Officer 2022-09-02 Option exercise +32 $7.49 $240 9,032 D
AULIN SHERRY Chief Financial Officer 2022-09-02 Option exercise +813 $8.40 $6,829 9,845 D
AULIN SHERRY Chief Financial Officer 2022-09-02 Option exercise +2,292 $3.10 $7,105 12,137 D
AULIN SHERRY Chief Financial Officer 2022-09-02 Option exercise +6,511 $4.75 $30,927 18,648 D
AULIN SHERRY Chief Financial Officer 2022-09-02 Shares withheld for taxes −3,293 $39.53 $130,172 15,355 D
AULIN SHERRY Chief Financial Officer 2022-09-02 Sale −15,355 $39.57 $607,597 0 D
Derivatives
AULIN SHERRY Chief Financial Officer 2022-09-02 Option exercise · Stock Option (Right to Buy) −9,000 0 D
AULIN SHERRY Chief Financial Officer 2022-09-02 Option exercise · Stock Option (Right to Buy) −32 0 D
AULIN SHERRY Chief Financial Officer 2022-09-02 Option exercise · Stock Option (Right to Buy) −813 0 D
AULIN SHERRY Chief Financial Officer 2022-09-02 Option exercise · Stock Option (Right to Buy) −2,292 0 D
AULIN SHERRY Chief Financial Officer 2022-09-02 Option exercise · Stock Option (Right to Buy) −6,511 0 D
Open-market sales · 15,355 sh · avg $39.57 · $607,597
Loading xslF345X03/doc4.xml…